Angimmune LLC
🇺🇸United States
A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2016-12-13
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- Angimmune LLC
- Target Recruit Count
- 63
- Registration Number
- NCT02990416
- Locations
- 🇺🇸
James Graham Brown Cancer Center, Louisville, Kentucky, United States
Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides
- First Posted Date
- 2016-10-25
- Last Posted Date
- 2016-10-25
- Lead Sponsor
- Angimmune LLC
- Target Recruit Count
- 162
- Registration Number
- NCT02943642
A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2016-11-23
- Lead Sponsor
- Angimmune LLC
- Target Recruit Count
- 2
- Registration Number
- NCT01888081
- Locations
- 🇺🇸
James Graham Brown Cancer Center, Louisville, Kentucky, United States
A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-02-08
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- Angimmune LLC
- Target Recruit Count
- 32
- Registration Number
- NCT00611208
- Locations
- 🇺🇸
Yale University School Of Medicine Recruiting, New Haven, Connecticut, United States
🇺🇸James Graham Brown Cancer Center, Louisville, Kentucky, United States
🇺🇸Scott and White Hospital & Clinic, Temple, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath